Immunitybio Stock Based Compensation To Revenue from 2010 to 2025
| IBRX Stock | USD 2.81 0.10 3.69% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 2.33516446 | Current Value 2.22 | Quarterly Volatility 523.09537243 |
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 M, Interest Expense of 138.2 M or Selling General Administrative of 100.2 M, as well as many indicators such as Price To Sales Ratio of 115, Dividend Yield of 0.0 or Days Sales Outstanding of 55.5. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
Immunitybio | Stock Based Compensation To Revenue |
Latest Immunitybio's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Immunitybio over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Immunitybio's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Immunitybio Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 514.47 | |
| Geometric Mean | 113.20 | |
| Coefficient Of Variation | 101.68 | |
| Mean Deviation | 469.36 | |
| Median | 822.16 | |
| Standard Deviation | 523.10 | |
| Sample Variance | 273,629 | |
| Range | 1.7K | |
| R-Value | (0.76) | |
| Mean Square Error | 124,781 | |
| R-Squared | 0.57 | |
| Significance | 0.0007 | |
| Slope | (83.27) | |
| Total Sum of Squares | 4.1M |
Immunitybio Stock Based Compensation To Revenue History
About Immunitybio Financial Statements
Immunitybio investors use historical fundamental indicators, such as Immunitybio's Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 2.34 | 2.22 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.